Compare IDXX & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDXX | NTRA |
|---|---|---|
| Founded | 1983 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.4B | 39.1B |
| IPO Year | 1996 | 2015 |
| Metric | IDXX | NTRA |
|---|---|---|
| Price | $556.20 | $258.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 15 |
| Target Price | ★ $721.67 | $259.07 |
| AVG Volume (30 Days) | 592.1K | ★ 1.1M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.59 | 0.65 |
| EPS | ★ 3.47 | N/A |
| Revenue | ★ $4,303,702,000.00 | $210,939,000.00 |
| Revenue This Year | $10.88 | $18.08 |
| Revenue Next Year | $8.59 | $19.65 |
| P/E Ratio | $156.86 | ★ N/A |
| Revenue Growth | ★ 10.42 | N/A |
| 52 Week Low | $518.55 | $131.81 |
| 52 Week High | $769.98 | $288.04 |
| Indicator | IDXX | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 50.84 | 50.49 |
| Support Level | $549.60 | $186.96 |
| Resistance Level | $583.93 | $288.04 |
| Average True Range (ATR) | 16.50 | 10.42 |
| MACD | -1.00 | -3.74 |
| Stochastic Oscillator | 47.99 | 15.47 |
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.